CorDx is a multinational biotechnology company specialising in rapid testing and point-of-care medical device solutions for infectious diseases and other health needs. Its proprietary diagnostic products - spanning infectious disease detection (including COVID-19), pregnancy testing, drug screening, and biomarker detection - hold CE Marks and approvals from regulatory bodies including the FDA, serving both healthcare providers and consumers. The company employs more than 2,100 people and maintains manufacturing operations in the United States as well as internationally.
The company operates across more than 100 countries and, through the broader CorDx Union ecosystem, claims a reach extending to over a billion users in 170+ countries. Its supply chain is vertically integrated, with strategic manufacturing footprints designed to support global distribution at scale.
CorDx positions its work at the intersection of diagnostics, artificial intelligence, and data science, with active research and development underpinning its product portfolio. The company's stated focus is on expanding access to reliable, rapid diagnostics across both clinical and consumer health settings worldwide.
